HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The molecular pathogenesis of the myelodysplastic syndromes.

Abstract
Recent studies have greatly illuminated the genomic landscape of the myelodysplastic syndromes (MDS), and the pace of discovery is accelerating. The most common mutations found in MDS occur in genes involved in RNA splicing (including SF3B1, SRSF2, U2AF1, and ZRSR2) and epigenetic modification (including TET2, ASXL1, and DNMT3A). The identification of spliceosome mutations in approximately half of all patients with MDS implicates abnormalities of RNA splicing, a pathway not previously known as a target for mutation, in the MDS pathogenesis. Several regulators of signal transduction (NRAS, JAK2) and transcription factors (RUNX1, TP53) are also frequently mutated in MDS. The complex patterns of associations between gene mutations identified have revealed epistatic interactions between spliceosome components and epigenetic modifiers in MDS. The cytogenetic abnormalities found in MDS are characterized by the loss of genetic material, whereas translocations are rare. The cytogenetic deletion maps of MDS (e.g., 5q-, 7q-, 20q-) provide us with circumstantial evidence for the presence of tumor suppressor genes. It is now recognized that haploinsufficiency (a gene dosage effect) resulting from gene deletions or inactivating mutations is an important disease mechanism in MDS. Haploinsufficiency of the ribosomal protein gene RPS14 plays a critical role in the development of anemia in the 5q- syndrome, and haploinsufficiency of CUX1 is important in some patients with MDS and AML with complete or partial loss of chromosome 7. Gene expression profiling has identified key deregulated genes and pathways and new prognostic gene signatures in MDS. Recent advances in the molecular pathogenesis of MDS are leading to new biological, clinical, and therapeutic insights.
AuthorsAndrea Pellagatti, Jacqueline Boultwood
JournalEuropean journal of haematology (Eur J Haematol) Vol. 95 Issue 1 Pg. 3-15 (Jul 2015) ISSN: 1600-0609 [Electronic] England
PMID25645650 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Copyright© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Chemical References
  • Ribonucleoproteins
  • Transcription Factors
  • DNA (Cytosine-5-)-Methyltransferases
Topics
  • Chromosome Deletion
  • Chromosomes, Human, Pair 5
  • Cri-du-Chat Syndrome
  • DNA (Cytosine-5-)-Methyltransferases (genetics, metabolism)
  • Epigenesis, Genetic
  • Haploinsufficiency
  • Humans
  • Mutation
  • Myelodysplastic Syndromes (diagnosis, genetics, metabolism, pathology)
  • Prognosis
  • RNA Splicing
  • Ribonucleoproteins (genetics, metabolism)
  • Spliceosomes
  • Transcription Factors (genetics, metabolism)
  • Trisomy

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: